Evidence map›Paper›PMID 32369348›Full record

ArticleACS applied materials & interfaces2020

Full-Spectrum

Almog Uziel, Anat Gelfand, Keren Amsalem, Paula Berman, Gil M Lewitus, David Meiri, Dan Y Lewitus

Open access · hybridAbstract readVideo-Audio Media
In one paragraph

Article in ACS applied materials & interfaces, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Frontiers in pharmacology · 2022
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Almog UzielDepartment of Polymers and Plastics Engineering, Shenkar College of Engineering, Design and Art, Ramat-Gan 52526, Israel.
Anat GelfandThe Laboratory of Cancer Biology and Cannabinoid Research, Department of Biology, Technion-Israel Institute of Technology, Haifa 320003, Israel.
Keren AmsalemThe Laboratory of Cancer Biology and Cannabinoid Research, Department of Biology, Technion-Israel Institute of Technology, Haifa 320003, Israel.
Paula BermanThe Laboratory of Cancer Biology and Cannabinoid Research, Department of Biology, Technion-Israel Institute of Technology, Haifa 320003, Israel.ORCID http://orcid.org/0000-0002-6821-3307
Gil M LewitusThe Laboratory of Cancer Biology and Cannabinoid Research, Department of Biology, Technion-Israel Institute of Technology, Haifa 320003, Israel.
David MeiriThe Laboratory of Cancer Biology and Cannabinoid Research, Department of Biology, Technion-Israel Institute of Technology, Haifa 320003, Israel.
Dan Y LewitusDepartment of Polymers and Plastics Engineering, Shenkar College of Engineering, Design and Art, Ramat-Gan 52526, Israel.ORCID http://orcid.org/0000-0002-6794-7413
Technion – Israel Institute of Technology · ILShenkar College of Engineering and Design · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic effect of the

Indexed as

AnimalsAnticonvulsantsCannabidiolCannabisDelayed-Action PreparationsDrug LiberationMicePentylenetetrazolePlant ExtractsSeizuresAnticonvulsantsCannabidiolDelayed-Action PreparationsPentylenetetrazolePlant Extractsanticonvulsant effectscontrolled releasefull-spectrum cannabismicrospheresphytocannabinoids

Identifiers

PMID32369348
PMCPMC7467538
OpenAlexW3021828828

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.